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OBJECTIVES: To estimate the value of survival gains in myelodysplastic syndromes 
(MDS) attributable to the introduction of azacitidine (2004), lenalidomide (2005), 
and decitabine (2006). METHODS: Using multivariate Cox proportional hazards 
models we estimated the increase in survival associated with the introduction 
of new therapies for MDS patients diagnosed from 2001–2011 in the Surveillance, 
Epidemiology, and End Results program registries. The key variable in the haz-
ard model was the post-2006 indicator, which captured the increase in survival 
associated with the introduction of the 3 therapies relative to years 2001–2003. 
Importantly, we included flexible specifications of time trends to capture secular 
changes in survival over the study period. We estimated the cost and utiliza-
tion of the 3 therapies from 2006–2012 using the Optum Touchstone commercial 
claims database. RESULTS: For 38,085 MDS patients diagnosed in 2001 or later 
we estimated that the introduction of these 3 therapies was associated with a 
hazard ratio of 0.901 (p< 0.10). Approximately 25% of MDS patients used at least 
1 of the 3 treatments over this period, implying an increase in median survival 
from 33 to 57.5 months, conditional on treatment observed in the community. 
Using an existing economic model to value survival gains, we estimated that 
the annual value of survival gains associated with the new therapies—i.e., the 
amount patients would be willing to pay for the improved survival profile—
equaled $208,000 per year. Based on this, we estimate the net present value 
of the therapies to all future patients at $101.5 billion. Net of treatment costs, 
85% of the total value accrues to patients. CONCLUSIONS: This study meas-
ured the value of survival gains attributable to 3 novel therapies for MDS and 
found significant benefits. For current and future MDS patients, these thera-
pies will generate $101.5B in value from survival gains, with 85% accruing to 
patients.
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OBJECTIVES: Comprehensive Medicaid population based studies of adherence 
and persistence to tamoxifen and aromatase inhibitors (AIs) including anastro-
zole, exemestane, and letrozole among women with breast cancer are currently 
lacking. The purpose of this study was to estimate the adherence and persistence 
to tamoxifen and AIs among women with breast cancer enrolled across 38 state 
Medicaid programs. Factors predicting adherence and persistence to tamoxifen 
and AIs were also determined. METHODS: Study population included women aged 
18-64 years who were continuously enrolled for a period of three years (2006-2008) 
in Medicaid managed care program across 38 states. Incident users of tamoxifen 
and AIs in 2007 were identified. To assess adherence (proportions of days covered) 
and persistence (gap between prescription refills) to tamoxifen and/or AIs among 
the final sample of women recipients with breast cancer, prescription drug claims 
from index date to 12-month post index date were studied. Logistic regression was 
used to identify predictors of adherence and persistence, respectively. RESULTS: 
Roughly 56% of women with breast cancer were adherent with tamoxifen 
and/or AIs therapy. Higher age, white race (versus black), geographic location in 
Northeast region (versus South, Midwest, and West region), stage II or III/IV (ver-
sus stage 0), and higher number of outpatient visits were associated with higher 
adherence in the regression model. More than three-fourths (~77%) of women 
with breast cancer were persistent with tamoxifen and/or AIs therapy. Regression 
analysis revealed that women with breast cancer residing in Northeast region 
(versus South and West region) and with stage I or III/IV cancer (versus stage 0) 
were more likely to be persistent with therapy. CONCLUSIONS: Adherence and 
persistent to tamoxifen and AIs was less than optimal among women with breast 
cancer enrolled in Medicaid programs. Policy makers should consider implement-
ing interventions aimed at increasing treatment adherence and persistence among 
this population.
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OBJECTIVES: Lenalidomide is a disease-modifying oral medication approved 
for the treatment of multiple myeloma as well as other myelodysplastic syn-
dromes. A CarePak® is a drug regimen packaging tool that simplifies complex 
drug regimens for patients. This tool is frequently used for patients receiving 
drug regimens containing lenalidomide. The impact of this tool on duration of 
therapy has previously not been studied. METHODS: This study was a retro-
spective review of pharmacy claims data. Eligible patients included those who 
filled a lenalidomide prescription more than once, did not have a gap between 
fills longer than 60 days. Patients receiving a CarePak® must have received one 
with all of their dispenses and for at least 6 consecutive months. Duration of 
therapy was calculated as the time between a patient’s first and last fill, includ-
ing the most recent day’s supply. RESULTS: A random sample of patients filling 
between 2009 and 2014 was used for this analysis. To assess differences in dura-
tion of therapy, 225 patients receiving CarePaks® and 225 patients not receiving 
CarePaks® were identified. Duration of therapy for patients utilizing CarePaks® 
and for patients not utilizing CarePaks® was10.5 months and 8.4 months respec-
tively, representing a difference of 2.1 months (p = 0.001). CONCLUSIONS: The 
use of CarePaks® significantly improved duration of therapy in patients receiving 
lenalidomide compared to patients not using CarePaks®. The result of this analysis 
suggests a need for further investigation into the impact of CarePaks® on patient 
outcomes.
ducted on the MedAssets health system data for inpatient and outpatient visits 
diagnosed with MCL for the January 2009 to December 2014 timeframe. Age and 
gender, clinical comorbidities and measures of utilization including number of 
visits and length of stay (LOS) were described. Multivariable regression was used to 
identify significant drivers of hospital-based utilization. RESULTS: The MCL popula-
tion consisted primarily of males (70.8%) and had a mean age of 66 years. Of 35,762 
visits 84.6% occurred in the outpatient setting. Infection (OR= 7.4, p< .0001), fluid and 
electrolyte disorders (OR= 6.3, p< .0001), plegia (OR= 5.9, p< .01), myelosuppression 
(OR= 5.2, p< .0001) and nutritional deficiencies (OR= 3.3, p< .0001) were associated 
with inpatient admissions. The most common complications of treatment included 
myelosuppression (21.7%), gastrointestinal issues (GI, 7.3%), infection (4.9%) and 
renal deficiency (4.8%). Pharmacy (49.2%), room and board (12.8%), laboratory testing 
(10.2%), diagnostic services (7.8%), and surgery (5.8%) costs were the most common 
in this population. When patients were admitted the average LOS was 8.3 days with 
an average cost of $18,291 and 5.0% in-hospital mortality rate. During inpatient hos-
pitalizations 55.0% received chemotherapy, 26.1% had a blood transfusion, 5.2% had 
a bone marrow biopsy, 4.4% had a stem cell transplant, 2.3% had hemodialysis and 
1.5% had radiotherapy. Nutritional deficiencies (IRR= 1.55, p< .0001), plegia (IRR= 1.51, 
p< .0001), infection (IRR= 1.46, p< .0001), myelosuppression (IRR= 1.34, p< .0001) and GI 
(IRR= 1.3, p< .0001) were associated with longer LOS. Readmissions occurred within 
30 days for 28.6% of inpatient admissions with 41.4% of readmissions having main-
tenance chemotherapy or radiotherapy as the primary diagnosis. CONCLUSIONS: 
MCL patients primarily use outpatient services. Inpatient services are required to 
treat complications of treatment such as myelosuppression and infections as well 
as to provide follow-up treatments and care.
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OBJECTIVES: The objective of this analysis was to describe hospital-based resource 
utilization among a population of patients with polycemia vera (PCV). METHODS: 
A retrospective cohort analysis was conducted on a cross-section of patients using 
hospital-based inpatient (N= 7974) and outpatient (N= 47078) services between 2013 
and 2014 with a diagnosis of PCV. Multivariate logistic regression was used to evalu-
ate risk factors for readmission controlling for patient and hospital characteristics 
as well as patient comorbidities. RESULTS: The mean age for PCV patients was 64.4 
years with 58.5% male. Utilization was highest in the OP setting (85.5%) with 68.3% of 
OP visits having a primary diagnosis of PCV. The primary diagnosis for IP admissions 
varied with the most common including infectious and parasitic diseases (6.6%), 
cerebrovascular disease (6.2%), chronic obstructive pulmonary disease (5.5%), heart 
failure (5.2%) and ischemic heart disease (5.2%). PCV patients were primarily treated 
in large (68.4%) and teaching (60.3%) hospitals. The mean Charlson comorbidity 
score was 1.6 with chronic pulmonary disease (18.4%), diabetes (16.7%), congestive 
heart failure (10.3%), cardiovascular disease (10.0%) and renal disease (10.0%) as the 
most common comorbidities. Readmissions occurred within 30 days for 9.0% of IP 
visits for a variety of diagnoses including rehabilitation services (10.9%), chest pain/
shortness of breath (6.8%), infectious and parasitic diseases (4.9%), cerebrovascu-
lar disease (4.1%) and respiratory failure (3.9%). Chronic pulmonary disease (OR = 
1.25, p< .05), hemiplegia or paraplegia (OR = 1.73, p< .05), renal disease (OR = 1.51, 
p< .001) and abdominal drainage procedures (OR = 2.60, p< .01) were associated with 
increased occurrence of readmission. CONCLUSIONS: PCV is primarily managed 
in the community or OP setting. As PCV-related complications develop patients are 
admitted for IP services. These patients are frequently readmitted within 30 days.
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OBJECTIVES: To estimate the economic impact in the treatment of Colombian 
patients with Non-Hodgkin lymphoma developing a time and motion study for the 
IV administration versus subcutaneous (SC) presentation of rituximab. METHODS: 
Time and motion study, observational, multicentric (two private hospitals, one pub-
lic hospital), non-interventional describing costs and times from the admission of 
the patient until their discharge, recording healthcare professionals (HPC), drugs, 
consumables and procedures room. Population evaluated were patients in first 
chemotherapy with rituximab IV with diffuse large B-cell lymphoma and follicu-
lar lymphoma, in regular cycles and in maintenance phase. Finally, we calculated 
the time and cost differences of the treatment of patients with SC (drug still non 
approved in Colombia, therefore these data was obtained from Rule et al., 2014) 
instead IV rituximab from the perspective of the provider. RESULTS: Patients were 
treated with rituximab IV at doses between 520 mg and 700 mg. If they had been 
treated with SC, it estimated to cause net savings of $360 USD per patient, which 
were represented in costs of healthcare professionals (HPC), drugs, consumables 
and procedures room and around 207 minutes of total time expenditure. The cost 
of rituximab SC is the most important savings factor to the provider because it is 
administrated at constant doses non-weight depended. CONCLUSIONS: Rituximab 
SC was a cost-saving strategy for the providers compared with Rituximab IV. As 
results of the savings in cost of treatment, consumables, procedures room and total 
time expenditure, the actual resources of the health provider could be optimized.
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